Intradermal XXXX prevent @entity1184 in a @entity95 ear model: a clinical, histological and spectroscopical analysis.

@entity1 @entity1184 @entity95 @entity2805 @entity1140
BACKGROUND: Keloids and @entity2805 ( @entity2805 ) affect 4.5-16% of the population. Thus far, the different approaches of keloid treatment are not very efficient, with a 50% relapse rate and many ongoing researches are looking for simple, safe and more efficient therapeutic methods. @entity1140 is an immunomodulator that could be useful in treating keloid. OBJECTIVES: The objective of this study is to evaluate the effectiveness of @entity1140 in inhibiting @entity2805 formation on @entity95 ' ears model and to check optical skin spectroscopy in tissue characterization. METHODS: Our study was carried out on 20 New-Zealand female white @entity95 . @entity2805 were obtained by wounding @entity95 ' ear. These wounds were treated with intradermal injections of @entity1140 (0.2-0.5 mg/cm(2)) or a vehicule. The assessment of treatment efficacy was performed by clinical examinations, histological assay and skin spectrometry. RESULTS: @entity1140 did not induce general or local side-effects. The scar elevation index in treated subjects was half less than that of the untreated ones. Furthermore, dermal thickness and inflammatory cellular density were both significantly smaller for treated scars than for the control ones. In vivo optical skin spectroscopy can characterize @entity1184 and normal skin with high sensibility and specificity. CONCLUSION: Intradermal injection of @entity1140 at 0.5 mg/cm(2) is an efficient way to prevent @entity2805 in our experiment model and its tolerance is correct. Optical spectroscopy could be a good non-invasive tool to evaluate @entity2805 treatment. These promising results might be proposed for @entity1 suffering from keloid.
